VEXED SURGEONS, PERPLEXED PATIENTS, AND BREAST CANCERS WHICH MAY NOT BE CANCER
VEXED SURGEONS, PERPLEXED PATIENTS, AND BREAST CANCERS WHICH MAY NOT BE CANCER
复制标题
DOI：
10.1002/1097-0142(19900201)65:3
复制
发表时间：
1990-02-01
期刊：
影响因子：
6.2
通讯作者：
MOFFAT, FL
中科院分区：
文献类型：
--
作者：
KETCHAM, AS;MOFFAT, FL
在这种情况下，由于乳房x光检查的广泛使用和病理学家对这些病变的认识提高，乳腺癌的诊断频率越来越高。这些浸润前癌症的治疗是有争议的，因为最近的数据支持小浸润性癌症的保乳治疗。本文讨论了原位乳腺癌的治疗，并关注了已知的复发和乳腺癌相关死亡率的危险因素。围绕导管癌和小叶癌治疗的争议迫使有责任心的肿瘤学家寻求充分的知情同意，并尊重个体患者对美容和乳腺癌风险的感受。有希望的是，前瞻性随机研究，如国家乳腺和肠外科辅助项目（NSABP） B‐17试验，将减轻肿瘤学界对这些疾病的自然史和最佳治疗方法的困惑。
In situcancer of the breast is being diagnosed with increasing frequency due to the widespread use of mammography and heightened awareness of these lesions among pathologists. Treatment of these preinvasive cancers is controversial in light of recent data supporting breast‐conserving therapy for small invasive cancers. Therapy forin situbreast cancer is discussed with attention to known risk factors for recurrence and breast cancer‐related mortality. The controversies surrounding treatment of ductal and lobular carcinomain situcompel the conscientious oncologist to seek fully informed consent and to respect the individual patient's feelings about cosmesis and breast cancer risk. Hopefully, prospective randomized studies such as the National Surgical Adjuvant Breast and Bowel Project (NSABP) B‐17 trial will relieve the oncology community of much of its confusion about the natural history and optimal therapy for these diseases.